The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

Part of paid clinical trials in Cooperstown, New York.

Sponsor
Bassett Healthcare
Study ID
NCT07556107
Phase
PHASE4
Status
Recruiting

Conditions

  • Acute Kidney Injury
  • Infection
  • Sepsis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Piperacillin + Tazobactam — DRUG
    PT Dosing (concealed): PT dosing is standard irrespective of infection severity. 4.5 gm IV loading dose over 30 min, then 4.5 g IV over 4 hr (extended infusion) 6 hrs after the loading dose, and then q 8 hr
  • meropenem — DRUG
    M dosing (concealed): M dosing depends on infection severity. 1 gm loading IV dose over 30 min, then 1 gm IV over 4 hr (extended infusion) q 8 hr (default dosing). Clinician has option to increase to 2 gm IV q 8 hr for severe infections and to decrease back to default dosing if previously chosen higher dosing is no longer deemed indicated.

Study Details

The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.

Key Dates

First listed
Apr 29, 2026
Start date
Aug 17, 2026
Status verified
Aug 2026
Primary completion
Jun 30, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
852 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Piperacillin/tazobactam
    Vancomycin plus piperacillin/tazobactam
  • Active Comparator: Meropenem
    Vancomycin plus meropenem

Primary Outcome Measure

Serum cystatin C (Scys) [ Time Frame: 7 days ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Bassett Medical CenterCooperstownNew York13326
Jennifer Victory
6075476965
Wake Forest University Health SciencesWinston-SalemNorth Carolina27157
Karen Ayala Baylon
(336) 716-5044
Christine Rogers
(336) 716-3978
John Williamson, PharmD (PRINCIPAL_INVESTIGATOR)
West Virginia UniversityMorgantownWest Virginia26506
Karen Hunter
(304) 293-7348
Daphne-Dominique Villanueva, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Cooperstown, NY

Related Studies